Literature DB >> 1955381

Long-lasting accumulation of vinblastine in inostamycin-treated multidrug-resistant KB cells.

M Kawada1, K Umezawa.   

Abstract

Inostamycin, a novel polyether compound, reverses multidrug resistance in KB cells. The mechanism of its action was studied by use of radioactively labeled vinblastine. Inostamycin dose-dependently increased the accumulation of [3H]vinblastine in multidrug-resistant KB-C4 cells at 0.5-2 micrograms/ml, while it did not enhance accumulation in the drug-sensitive KB-3-1 cells. At a concentration of 1 microgram/ml inostamycin inhibited active [3H]vinblastine efflux from KB-C4 cells, but not from KB-3-1 cells, and inhibited [3H]vinblastine binding to KB-C4 membranes with an IC50 of 0.94 microgram/ml (1.3 microM). Furthermore, [3H]vinblastine accumulated by treatment with 1 microgram/ml of inostamycin was resistant to efflux from KB-C4 cells, even after the removal of inostamycin.

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1955381      PMCID： PMC5918255          DOI： 10.1111/j.1349-7006.1991.tb01771.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN： 0910-5050


  18 in total

Review 1.  Multidrug resistance.

Authors:  A M van der Bliek; P Borst
Journal:  Adv Cancer Res       Date:  1989       Impact factor: 6.242

2.  Characteristics of resistance to adriamycin in human myelogenous leukemia K562 resistant to adriamycin and in isolated clones.

Authors:  T Tsuruo; H Iida-Saito; H Kawabata; T Oh-hara; H Hamada; T Utakoji
Journal:  Jpn J Cancer Res       Date:  1986-07

3.  Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells.

Authors:  K Yusa; T Tsuruo
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

4.  ATP/Mg2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells.

Authors:  M Naito; H Hamada; T Tsuruo
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

5.  Reversal of resistance to vincristine in P388 leukemia by various polycyclic clinical drugs, with a special emphasis on quinacrine.

Authors:  M Inaba; E Maruyama
Journal:  Cancer Res       Date:  1988-04-15       Impact factor: 12.701

6.  Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance.

Authors:  H L Pearce; A R Safa; N J Bach; M A Winter; M C Cirtain; W T Beck
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

7.  Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines.

Authors:  A Fojo; S Akiyama; M M Gottesman; I Pastan
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

8.  Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines.

Authors:  N Kartner; J R Riordan; V Ling
Journal:  Science       Date:  1983-09-23       Impact factor: 47.728

9.  Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells.

Authors:  I B Roninson; J E Chin; K G Choi; P Gros; D E Housman; A Fojo; D W Shen; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-06       Impact factor: 11.205

10.  Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro.

Authors:  L M Slater; P Sweet; M Stupecky; S Gupta
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808
View more
  2 in total

1.  Potentiation of paclitaxel cytotoxicity by inostamycin in human small cell lung carcinoma, Ms-1 cells.

Authors:  S Simizu; K Tanabe; E Tashiro; M Takada; K Umezawa; M Imoto
Journal:  Jpn J Cancer Res       Date:  1998-09

2.  Inostamycin, an inhibitor of P-glycoprotein function, interacts specifically with phosphatidylethanolamine.

Authors:  M Kawada; K Umezawa
Journal:  Jpn J Cancer Res       Date:  1995-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.